scPharmaceuticals (SCPH) Provides Business Update on FUROSCIX

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today provided a business update on FUROSCIX®, its investigational proprietary formulation of furosemide for subcutaneous administration.

“As we look forward to our upcoming December 30, 2020 PDUFA date for FUROSCIX, we are building out what we believe is a world-class commercial team capable of executing a successful product launch, if approved,” stated John Tucker, president and chief executive officer of scPharmaceuticals. “In addition, our three posters at this year’s Heart Failure Society of America virtual meeting contributed to the growing body of evidence suggesting that FUROSCIX has the potential to be a cost-effective treatment for congestion in patients with heart failure outside the hospital. This is a significant unmet medical need highlighted by Drs. Bensimhon and Desai during our recent Key Opinion Leader webinar. We believe FUROSCIX can help to address this need.”

Commercial Preparedness Activities

To prepare for the launch of FUROSCIX, if approved, the Company has made key additions to its commercial team, including vice presidents of marketing, sales and market access. In addition, recruitment for the Company’s field sales team is ongoing and remains closely aligned with currently anticipated regulatory timelines.

12 Month Drug Stability Data

The Company has submitted twelve-month drug stability data to the U.S. Food and Drug Administration (FDA). Pursuant to an agreement with the FDA, scPharmaceuticals was permitted to submit its New Drug Application (NDA) with nine months of drug stability data and submit the remining three months during the FDA’s review. All drug stability data has now been submitted.

Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting 2020

scPharmaceuticals participated in three virtual poster presentations at the HFSA Virtual Annual Scientific Meeting 2020. Posters included:

1. FUROSCIX Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure - (FREEDOM-HF)
   • The methods for an ongoing, interventional clinical trial evaluating the economic impact of treating patients who present to the emergency department with worsening heart failure due to congestion with FUROSCIX outside the hospital setting are described.
   
2. Heart Failure Related Costs and Health Care Resource Utilization Following an Emergency Department (ED) Visit for Worsening Heart Failure: A Claims Data Analysis
   • Patients hospitalized for less than 72 hours after presenting to the ED for worsening heart failure (WHF) have average 30-day all-cause and heart failure related costs of $19,560 and $14,283, respectively.
   
   • Patients presenting to the ED for WHF and not hospitalized have 30-day all-cause and heart failure related outpatient costs of $6,401 and $5,034, respectively.
   
3. Successful Validation of a Wearable, On-Body Infusor for Subcutaneous Administration of FUROSCIX in Heart Failure Patients, Caregivers, and Health Care Practitioners
   • Patients with heart failure, caregivers and health care providers followed the Instructions for Use (IFU) to safely and effectively operate the On-Body Infusor for FUROSCIX where-by no patterns of use errors were observed in both trained and untrained participants.

Key Opinion Leader Webinar

On September 29, 2020, scPharmaceuticals hosted a successful key opinion leader (KOL) webinar on FUROSCIX. The webinar featured presentations by Dan Bensimhon, M.D. of Cone Health Medical Group and Nihar Desai, M.D., MPH from the Yale School of Medicine who discussed the current treatment landscape and unmet medical need that exists in treating patients with worsening heart failure due to congestion. A replay of the webinar is available here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Travere Therapeutics (TVTX) PT Raised to $19 at H.C. Wainwright
• Mangoceuticals (MGRX) Acquires Global Preventive Care Patent Portfolio